Clinical trial
An Efficacy and Safety Study for Epoetin Alfa (PROCRIT) in Cancer Patients Not…
NCT00210587 · Johnson & Johnson Pharmaceutical Research & Development, L.L.C., Industry · Completed
Key facts
| NCT number | NCT00210587 |
|---|---|
| Title | An Efficacy and Safety Study for Epoetin Alfa (PROCRIT) in Cancer Patients Not Receiving Chemotherapy or Radiation |
| Official title | A Pilot Study to Evaluate the Response Rate of Epoetin Alfa (PROCRIT) at 80,000 Units Every Three Weeks in Anemic Patients With Cancer Not Receiving Chemotherapy or Radiation Therapy |
| Lead sponsor | Johnson & Johnson Pharmaceutical Research & Development, L.L.C., Industry |
| Collaborators | Ortho Biotech Products, L.P. Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Anemia, Neoplasms |
| Intervention type | Drug |
| Interventions | epoetin alfa |
| Enrollment | 51 |
| Start date | Feb 1, 2005 |
| Completion | Dec 1, 2005 |
| First posted | Sep 21, 2005 |
| Last update posted | Jun 10, 2011 |
At a glance
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: